References
- Cowie M, Struthers A, Wood D, Coats A, Thompson S, Poole-Wilson P, Sutton G. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–1353
- Daggubati S, Parks J, Overton R, Cintron G, Schocken D, Vesely D. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovascular Research 1997; 36: 246–255
- Hunt P, Richards A, Nicholls M, Yandle T, Doughty R, Espiner E. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clinical Endocrinology 1997; 47: 287–296
- Cleland J, Ward S, Dutka D, Habib F, Impallomeni M, Morton J. Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature. Heart 1996; 75: 410–413
- Masuta K, Misaki A, Aono K, Shimizu H, Asada H, Teraoka H, Akioka H. Assessment of human brain natriuretic peptide stability in clinical samples. Clin Chem 1998; 44/6: A 130, Supplement
- Glick M., Ryder K., Jackson S. Graphical comparisons of interferences in clinical chemistry instrumentation. Clin Chem 1986; 32: 470–475